Spexis AG has released results from an in vitro study evaluating the effects of combining its potent CXCR4 inhibitor balixafortide (BLX) with several available conventional or targeted therapies in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback